Anixa Biosciences is a clinical-stage oncology company whose valuation is no longer riding on legacy patent licensing; the company is now being priced, in our view, almost entirely on the next two data prints from its two most advanced programs. On February 9, 2026, the company announced that patients in its Phase 1 ovarian cancer CAR-T (chimeric antigen receptor T-cell, a therapy that re-engineers a patient's own immune cells to hunt tumors) trial at the H. Lee Moffitt Cancer Center had shown encouraging survival signals and that regulators had cleared the company to dose-escalate beyond the levels baked into the original trial protocol. With thirteen patients now dosed across four ascending cohorts, including one patient who has survived twenty-eight months against a three-to-four month median, the lira-cel program is, in our reading, the single largest binary catalyst in the story.
The second leg is the breast cancer vaccine, where the Phase 1 read-out delivered in December 2025 at the San Antonio Breast Cancer Symposium, with seventy-four percent of subjects showing a protocol-defined immune response and the primary endpoints met, has set up a Phase 2 in the neo-adjuvant setting that should enter the clinic once the FDA protocol, manufacturing and site selection are wrapped. The single load-bearing risk is funding, and it is small but real: at April 30, 2026, Anixa held $13.7 million in cash and short-term investments, which the company says is enough for "significantly longer than twelve months," but a Phase 2 breast cancer vaccine trial plus a higher-dose lira-cel cohort will not be cheap, and the company's at-the-market (ATM) facility, a shelf-registered mechanism for dribbling small blocks of stock into the open market at prevailing prices, has $97 million of remaining authorized capacity, which is the funding bridge we expect to be drawn on.
The falsifiable clock is the next data print. We see three near-term events that will test the thesis: the next lira-cel cohort update from Moffitt, which we expect sometime in the second half of fiscal 2026, the initiation of the Phase 2 breast cancer vaccine trial, and the next set of interim survival numbers from the ovarian CAR-T patients who have now crossed the eighteen and twenty-eight month marks. The bear case is straightforward: if lira-cel efficacy does not harden in the higher-dose cohorts and the Phase 2 breast cancer vaccine does not begin enrolling on schedule, the stock is a clinical-stage oncology name with two early-stage assets, a $118 million market capitalization and no product revenue.